Catalyst Biosciences and Isu Abxis, a biologics manufacturing and development company based in Seoul Korea, have entered a collaboration to develop Catalyst’s next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B. The collaboration will advance FIX-NG through preclinical studies, manufacture, and the completion of Phase I studies designed to establish proof-of-mechanism.   Isu Abxis will be responsible for preclinical...